IDH2 and glioma: AMPK-mediated inhibition of the mammalian target of rapamycin (mTOR) signaling decreases protein synthesis, making IDH mutant glioma cells vulnerable to synthetic lethality through inhibition of B cell lymphoma-extra large (Bcl-xL).